{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:29:09Z","timestamp":1791311349266,"version":"4.3.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93464-w","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T17:04:04Z","timestamp":1743527044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors associated with increased severity of generalized myasthenia gravis among patients in the United States and Europe"],"prefix":"10.1038","volume":"15","author":[{"given":"Jacqueline","family":"Pesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zia","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"de Courcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Lauretta","family":"Birija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Chatterton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"93464_CR1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever Jr","year":"1983","unstructured":"Bever, C. T. Jr., Aquino, A. V., Penn, A. S., Lovelace, R. E. & Rowland, L. P. Prognosis of ocular myasthenia. Ann Neurol. 14, 516\u2013519 (1983).","journal-title":"Ann Neurol."},{"key":"93464_CR2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","volume":"52","author":"HJ Oosterhuis","year":"1989","unstructured":"Oosterhuis, H. J. The natural course of myasthenia gravis: A long term follow up study. J Neurol Neurosurg Psychiatry. 52, 1121\u20131127 (1989).","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"93464_CR3","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1007\/s00415-022-11316-3","volume":"269","author":"A Gu\u00e9guen","year":"2022","unstructured":"Gu\u00e9guen, A. et al. Generalization of ocular myasthenia gravis 10 years after onset. J Neurol. 269, 6597\u20136604 (2022).","journal-title":"J Neurol."},{"key":"93464_CR4","doi-asserted-by":"crossref","unstructured":"Li, F. et al. Prediction of the generalization of myasthenia gravis with purely ocular symptoms at onset: a multivariable model development and validation. Ther. Adv. Neurol. Disord. 15, 17562864221104508 (2022).","DOI":"10.1177\/17562864221104508"},{"key":"93464_CR5","doi-asserted-by":"crossref","first-page":"895007","DOI":"10.3389\/fimmu.2022.895007","volume":"13","author":"Z Ruan","year":"2022","unstructured":"Ruan, Z. et al. Development and validation of a nomogram for predicting generalization in patients with ocular myasthenia gravis. Front Immunol. 13, 895007 (2022).","journal-title":"Front Immunol."},{"key":"93464_CR6","first-page":"e1594","volume":"101","author":"CEH Fang","year":"2023","unstructured":"Fang, C. E. H., Bokre, D. & Wong, S. H. Clinical characteristics associated with secondary generalization in patients with ocular myasthenia gravis: A systematic review and meta-analysis. Neurology. 101, e1594\u2013e1605 (2023).","journal-title":"Neurology."},{"key":"93464_CR7","first-page":"175628641987652","volume":"12","author":"M Li","year":"2019","unstructured":"Li, M. et al. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: A systematic review and meta-analysis. Ther Adv Neurol Disord. 12, 1756286419876521 (2019).","journal-title":"Ther Adv Neurol Disord."},{"key":"93464_CR8","unstructured":"Jaretzki, A. et al. Myasthenia gravis: Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann. Thorac. Surg. 70, 327\u2013334 (2000)."},{"key":"93464_CR9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke, C. et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation. 19, 89 (2022).","journal-title":"J Neuroinflammation."},{"key":"93464_CR10","doi-asserted-by":"crossref","first-page":"e066445","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde, S. et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 13, e066445 (2023).","journal-title":"BMJ Open."},{"key":"93464_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob, D., Brunner, N., Namba, T. & Pagala, M. Lifetime course of myasthenia gravis. Muscle Nerve. 37, 141\u2013149 (2008).","journal-title":"Muscle Nerve."},{"key":"93464_CR12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","volume":"2","author":"VC Juel","year":"2007","unstructured":"Juel, V. C. & Massey, J. M. Myasthenia gravis. Orphanet J. Rare Dis. 2, 44 (2007).","journal-title":"Orphanet J. Rare Dis."},{"key":"93464_CR13","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson, P., Benford, M., Harris, N., Karavali, M. & Piercy, J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 24, 3063\u20133072 (2008).","journal-title":"Curr Med Res Opin."},{"key":"93464_CR14","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson, P. et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 39, 1707\u20131715 (2023).","journal-title":"Curr Med Res Opin."},{"key":"93464_CR15","doi-asserted-by":"crossref","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux, S. M., Curtis, B., Holbrook, T., Milligan, G. & Piercy, J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: The Disease Specific Programme. BMJ Open. 6, e010352 (2016).","journal-title":"BMJ Open."},{"key":"93464_CR16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins, V. et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 9, 371\u2013380 (2016).","journal-title":"Diabetes Metab Syndr Obes."},{"key":"93464_CR17","unstructured":"European Pharmaceutical Market Research Association. Code of Conduct https:\/\/www.ephmra.org\/sites\/default\/files\/2022-03\/2021%2520EPHMRA%2520Code%2520of%2520Conduct%25202.11.21.pdf (2021)."},{"key":"93464_CR18","unstructured":"US Department of Health & Human Services. Summary of the HIPAA Privacy Rule http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf (2020)."},{"key":"93464_CR19","unstructured":"US Department of Health & Human Services. Health Information Technology Act https:\/\/www.hhs.gov\/sites\/default\/files\/ocr\/privacy\/hipaa\/administrative\/enforcementrule\/enfifr.pdf?language=es (2009)."},{"key":"93464_CR20","doi-asserted-by":"crossref","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","volume":"97","author":"M Petersson","year":"2021","unstructured":"Petersson, M. et al. Patient-reported symptom severity in a nationwide myasthenia gravis cohort: Cross-sectional analysis of the Swedish GEMG study. Neurology. 97, e1382-1391 (2021).","journal-title":"Neurology."},{"key":"93464_CR21","doi-asserted-by":"crossref","unstructured":"Sobierajski, T., Lasek-Bal, A., Krzystanek, M. & Gilhus, N. E. Diagnosis and therapy of myasthenia gravis\u2014the patients\u2019 perspective: a cross-sectional study. Front. Neurol. 14 (2023).","DOI":"10.3389\/fneur.2023.1214041"},{"key":"93464_CR22","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer, S. et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 269, 3050\u20133063 (2022).","journal-title":"J Neurol."},{"key":"93464_CR23","first-page":"316","volume":"405","author":"K Yacouba","year":"2019","unstructured":"Yacouba, K., Kouda, D., Affognon, K., Bugeme, M. & Mourabit, S. Therapeutic itinerary of the patients followed for myasthenia in Dakar. J. Neurol. Sci. 405, 316 (2019).","journal-title":"J. Neurol. Sci."},{"key":"93464_CR24","doi-asserted-by":"crossref","unstructured":"Spillane, J., Higham, E. & Kullmann, D. Myasthenia gravis. BMJ (Clinical research ed.). 345, e8497 (2012).","DOI":"10.1136\/bmj.e8497"},{"key":"93464_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus, N. E. et al. Myasthenia gravis. Nat Rev Dis Primers. 5, 1\u201319 (2019).","journal-title":"Nat Rev Dis Primers."},{"key":"93464_CR26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.12816\/0003095","volume":"12","author":"A Al-Asmi","year":"2012","unstructured":"Al-Asmi, A., Nandhagopal, R., Jacob, P. C. & Gujjar, A. Misdiagnosis of myasthenia gravis and subsequent clinical implication: a case report and review of literature. Sultan Qaboos Univ Med J. 12, 103\u2013108 (2012).","journal-title":"Sultan Qaboos Univ Med J."},{"key":"93464_CR27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.nmd.2021.04.002","volume":"31","author":"AM Ruiter","year":"2021","unstructured":"Ruiter, A. M., Verschuuren, J. J. G. M. & Tannemaat, M. R. Prevalence and associated factors of fatigue in autoimmune myasthenia gravis. Neuromuscular Disorders. 31, 612\u2013621 (2021).","journal-title":"Neuromuscular Disorders."},{"key":"93464_CR28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami, P. et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 96, 114\u2013122 (2021).","journal-title":"Neurology."},{"key":"93464_CR29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/mus.28063","volume":"69","author":"J Pesa","year":"2024","unstructured":"Pesa, J. et al. The impact of myasthenia gravis severity on work and daily activities. Muscle Nerve. 69, 428\u2013439 (2024).","journal-title":"Muscle Nerve."},{"key":"93464_CR30","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00415-021-10759-4","volume":"269","author":"I Bozovic","year":"2022","unstructured":"Bozovic, I. et al. Long-term outcome in patients with myasthenia gravis: One decade longitudinal study. J Neurol. 269, 2039\u20132045 (2022).","journal-title":"J Neurol."},{"key":"93464_CR31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","volume":"13","author":"JS Bae","year":"2006","unstructured":"Bae, J. S., Go, S. M. & Kim, B. J. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 13, 1006\u20131010 (2006).","journal-title":"J Clin Neurosci."},{"key":"93464_CR32","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/bcp.14074","volume":"86","author":"R Roller-Wirnsberger","year":"2020","unstructured":"Roller-Wirnsberger, R., Thurner, B., Pucher, C., Lindner, S. & Wirnsberger, G. H. The clinical and therapeutic challenge of treating older patients in clinical practice. Br J Clin Pharmacol. 86, 1904\u20131911 (2020).","journal-title":"Br J Clin Pharmacol."},{"key":"93464_CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2022","unstructured":"Jackson, K. et al. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: A qualitative study. Neurol Ther. 12, 107\u2013128 (2022).","journal-title":"Neurol Ther."},{"key":"93464_CR34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mus.27443","volume":"65","author":"P Narayanaswami","year":"2022","unstructured":"Narayanaswami, P. et al. Identifying a patient-centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis. Muscle Nerve. 65, 75\u201381 (2022).","journal-title":"Muscle Nerve."},{"key":"93464_CR35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40120-021-00292-x","volume":"11","author":"RJ Guo","year":"2022","unstructured":"Guo, R. J. et al. Risk factors for generalization in patients with ocular myasthenia gravis: A multicenter retrospective cohort study. Neurol Ther. 11, 73\u201386 (2022).","journal-title":"Neurol Ther."},{"key":"93464_CR36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mus.27369","volume":"64","author":"J Vijayan","year":"2021","unstructured":"Vijayan, J. et al. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve. 64, 462\u2013466 (2021).","journal-title":"Muscle Nerve."},{"key":"93464_CR37","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1007\/s10072-023-06750-8","volume":"44","author":"HN Ozdemir","year":"2023","unstructured":"Ozdemir, H. N., Karasoy, H., Yuceyar, A. N. & Ekmekci, O. Effects of comorbid diseases on clinical outcomes in patients with myasthenia gravis. Neurol Sci. 44, 2923\u20132931 (2023).","journal-title":"Neurol Sci."},{"key":"93464_CR38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12883-022-02692-4","volume":"22","author":"L Harris","year":"2022","unstructured":"Harris, L., Graham, S., MacLachlan, S., Exuzides, A. & Jacob, S. A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. BMC Neurol. 22, 172 (2022).","journal-title":"BMC Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93464-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93464-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93464-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T06:44:38Z","timestamp":1743749078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93464-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93464"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93464-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jacqueline Pesa and Zia Choudhry are employees of Janssen Scientific Affairs, LLC and Johnson and Johnson stockholders. Jonathan de Courcy, Sophie Barlow, Shiva Lauretta Birija, Emma Chatterton, and Gregor Gibson are employees of Adelphi Real World. Bethan Hahn received payment as a contractor from Adelphi Real World for involvement in this manuscript, and also receives payment as a contractor from Janssen (Pharmaceutical Companies of Johnson and Johnson), Amiculum Limited, and McCann Health Medical Communications. Raghav Govindarajan serves on the advisory board for Argenx, Janssen, and UCB, and on the speakers bureau for Argenx and Alexion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Participating patients and physicians provided informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The MG DSP survey obtained ethics approval from the Western Institutional Review Board (WIRB; study protocol number: 1276240). Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and de-identified before receipt. Data collection was undertaken in line with relevant legislation and guidelines including European Pharmaceutical Marketing Research Association (EMPHMRA) guidelines17, the US Health Insurance Portability and Accountability Act (HIPAA) 199618, and Health Information Technology for Economic and Clinical Health (HITECH) Act legislation19.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}],"article-number":"11108"}}